Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2008
Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00932295 (Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Acute Effects of Electronic Nicotine Delivery Devices Marketed to Smokers.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Interventions to reduce harm from continued tobacco use.The Cochrane database of systematic reviews · 2016Pooled it
- Measures for assessing subjective effects of potential reduced-exposure products.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Pooled it
- Nicotine pharmacokinetics and subjective responses after using nicotine pouches with different nicotine levels compared to combustible cigarettes and moist smokeless tobacco in adult tobacco users.Psychopharmacology · 2022Trial
- Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes.Psychopharmacology · 2021Trial
- Acute effects of snus in never-tobacco users: a pilot study.The American journal of drug and alcohol abuse · 2018Trial
- Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Trial
- Evaluating oral noncombustible potential-reduced exposure products for smokers.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2010Trial
- Tobacco-use behavior and toxicant exposure among current dual users of electronic cigarettes and tobacco cigarettes.Experimental and clinical psychopharmacology · 2021Article
- Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation.Drug and alcohol dependence · 2015Article
- Nicotine Absorption from Smokeless Tobacco Modified to Adjust pH.Journal of addiction research & therapy · 2014Article
- Subjective responses to oral tobacco products: scale validation.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013Article
- Dependence on tobacco and nicotine products: a case for product-specific assessment.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2012Article
- Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.Tobacco control · 2010Article
- A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2010Article
- Abuse liability assessment of tobacco products including potential reduced exposure products.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Review
- Clinical trials methods for evaluation of potential reduced exposure products.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Several potential reduced exposure products (PREPs) for smokeless tobacco (SLT) users are marketed in the United States, though their effects are largely unknown. These products include some that are low in tobacco-specific nitrosamines (TSNs), like Stonewall, a pressed tobacco tablet, and General snus, a moist snuff product produced in Sweden. Methodology assessing the toxicant exposure and effects of cigarette-like PREPs for smokers has been developed, and might be modified for use in evaluating PREPs for SLT users. This report describes two studies examining the toxicant exposure and effects of two PREPs for SLT users. Study 1 (n = 13) consisted of four 4.5-hr laboratory sessions where SLT products (own brand, Stonewall, General snus, and tobacco-free placebo) were used for four 30-min episodes and nicotine exposure and tobacco/nicotine abstinence symptoms were measured. Study 2 (n = 19) consisted of four 5-day ad libitum use periods when participants used own brand, Stonewall, General snus, or no SLT and urinary levels of metabolites of nicotine (cotinine) and the TSN 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNAL) and abstinence symptoms were measured. Compared with own brand, Stonewall was associated with lower levels of cotinine and NNAL, while General snus was associated with similar levels of cotinine and lower levels of NNAL. Abstinence symptoms generally did not differ across tobacco conditions. These results show that clinical laboratory methods can be used to evaluate the toxicant exposure and abstinence symptom suppression associated with PREPs for SLT users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.